Literature DB >> 28890901

Performing all major surgical procedures robotically will prolong wait times for surgery.

Brian M Shinder1, Nicholas J Farber1, Robert E Weiss1,2, Thomas L Jang1,2, Isaac Y Kim1,2, Eric A Singer1,2, Sammy E Elsamra1,2.   

Abstract

This article aimed to assess the burden of scheduling major urologic oncology procedures if all cases were performed robotically and to determine whether this would increase the time a patient would have to wait for surgery. We retrospectively determined the number of prostatectomies, radical nephrectomies, partial nephrectomies, and cystectomies at a single institution for one calendar year. A hypothetical situation was then constructed where all procedures were performed robotically. Using the allotted number of days that each surgeon was able to schedule robotic procedures, we analyzed the amount of time it would take to schedule and complete all cases. Five fellowship-trained surgeons were included in the study and accounted for 317 surgical cases. Three of the surgeons had dedicated robotic surgery (RS) time (block time), while two surgeons scheduled when there was non-dedicated RS time (open time) available. If all cases were performed robotically an additional 32 days would be needed, which could significantly increase the wait time to surgery. The limited number of robotic systems available in most hospitals creates a bottleneck effect; whereby increasing the number of cases would considerably lengthen the waiting time patients have for surgery. As RS becomes increasingly more commonplace in urology and other surgical fields, this could create a significant problem for health care systems.

Entities:  

Keywords:  robotic; scheduling; surgical procedures

Year:  2017        PMID: 28890901      PMCID: PMC5586216          DOI: 10.2147/RSRR.S135713

Source DB:  PubMed          Journal:  Robot Surg        ISSN: 2324-5344


Introduction

Since receiving US Food and Drug Administration approval in the year 2000, the da Vinci Surgical System (Intuitive Surgical Inc, Sunnyvale, CA, USA) has become an integral tool for urologic surgeons. In just a few years it has been widely adopted for the treatment of a variety of urologic conditions. Robotic prostatectomy has become the standard of care for men in need of prostate cancer surgery, with the vast majority of prostatectomies now performed with robotic assistance.1,2 Additionally, partial and radical nephrectomies, cystectomies, pyeloplasties, and adrenal surgeries are now routinely done robotically, especially in large tertiary care centers. Robotic surgery (RS) offers many advantages over traditional open surgery, making it an attractive alternative to both the patient and surgeon. It was introduced to expand on the benefits of minimally invasive and laparoscopic surgical techniques, as well as reduce the difficulty in performing laparoscopic procedures, especially for laparoscopic-naïve surgeons.3 However, it is not without its pitfalls. One of the most common criticisms of RS is that the costs associated with it are much higher than that of open surgery. Various factors account for the higher cost, including the initial investment in purchasing the system, maintenance, disposable equipment fees, and longer operating room times.4,5 However, the potential clinical benefits of robotic surgery, including decreased post-operative pain, fewer blood transfusions, and shorter hospital stay make up for the increased costs of the procedure, especially at high-volume centers.6–8 As RS technology continues to advance and physicians increase the scope of surgical cases performed robotically, it is imperative to fully analyze the extent to which it can be implemented into clinical practice. In this respect, we constructed a model in which the most commonly performed urologic oncology procedures in a calendar year at a single institution were done robotically. Because the physicians are limited by the number of days allotted to them to use the robot, we hypothesized that performing all cases robotically would create a bottleneck effect, and the same caseload would not be able to be done in one calendar year.

Materials and methods

Robotic console scheduling

Our institution currently has two da Vinci robotic operating consoles available for use. They are shared among the urology (general urology, pediatric urology, and urologic oncology), gynecology (benign gynecology and gynecologic oncology), cardiothoracic, otolaryngology, general, colorectal, bariatric, and surgical oncology faculty, along with private practice physicians. Surgeons are allotted a certain number of days per month (“block time”) that they are able to schedule robotic surgeries, which is determined by hospital administration based on utilization and volume. At our institution, each surgeon is only permitted to run one operating room at a time, so concurrent RS is prohibited.

Data acquisition and projections

Following Institutional Review Board approval from Rutgers Robert Wood Johnson University Hospital, a complete list of surgical cases, both open and robotic surgery, completed by five fellowship-trained urologic surgeons was generated for a single calendar year (2015). All patient data was anonymized in order to maintain patient confidentiality. This list was queried for prostatectomy, partial nephrectomy, radical nephrectomy, and cystectomy. Block times were provided by the surgeon and confirmed by the surgery scheduling coordinator. During this study period, three of the five surgeons were allotted block time, while the remaining two surgeons were only able to schedule robotic cases when there were unused or open days (open time). Based on the average times to perform each particular surgery, we set the maximum number of robotic cases that would be able to be performed each day (“robotic days”) by a surgeon with two for radical nephrectomy, partial nephrectomy, prostatectomy, and one for cystectomy. We fitted the total number of cases that a surgeon had in the study year to this scheduling framework in order to model the scenario of all surgeries being performed robotically. We then projected the number of days needed for the five surgeons to complete their caseload and whether this could be done in a year based on the allotted block times.

Results

In total, 317 major oncologic procedures were performed by the five included surgeons at a single institution in one calendar year (Table 1). Block times were 8 days per month (96 per year) for surgeon #1, 2 days per month for surgeon #2 (24 per year), and 2 days per month for surgeon #3 (24 per year). Surgeon #4 and surgeon #5 did not have any allotted block time. Surgeon #1 performed 126 total cases, which would require 63 robotic days to complete based on the type of surgeries performed. With 96 days per year available, there would be 33 open days. Surgeon #2 had 42 total cases, which would take 22 robotic days to complete. This surgeon had 24 days available for the year, leaving 2 unused days. Surgeon #3 had 46 total cases, accounting for 26 robotic days. Surgeon #3 had only 24 days of block time, so 2 additional days would be needed to complete all the cases. Surgeons #4 and #5 did not have any allotted block time and performed 103 major oncologic surgeries, requiring 65 days based on the types of procedures.
Table 1

Surgeon caseload and block time data.

Total number of major oncologic surgeriesRobotic days needed (number/year)Block time (days/month)Block time (days/year)Projected unused daysProjected extra days needed
Surgeon #11266389633
Surgeon #242222242
Surgeon #346262242
Surgeon #49762N/aN/a62
Surgeon #563N/aN/a3

Abbreviaton: N/a, not applicable.

In total, there would be 35 unused days by surgeon #1 and #2, while surgeons #3, #4, and #5 would need 67 days. Scheduling permitting, an extra 32 days would then be needed for surgeons to perform the entire caseload robotically.

Discussion

The only commercially available RS platform, the da Vinci Surgical System, offers an improvement on traditional laparoscopic techniques. It employs a high-definition camera with a three-dimensional viewing system that allows up to 12× magnification. Additionally, the patented Endowrist technology mimics the user’s hand dexterity, in a scaled fashion, to give 7 degrees of freedom to the operating tools, while reducing physiological tremors to allow for precision movements.9 These factors have been suggested to yield shorter learning curves, and potentially improved surgical outcomes.3,10 Over the past decade, the utilization of RS in urology has substantially increased. Some of the most complex pelvic surgeries that were almost exclusively done with open techniques in the past have been successfully performed using the da Vinci robot. Reports of level III inferior vena cava thrombectomies, appendicovesicostomy, retroperitoneal lymph node dissection, pelvic exenteration, and other complex procedures have been described in the literature.11–14 RS may be well suited for these complex cases as the robotic arms eliminate the ergonomic challenges inherent in traditional laparoscopy and open surgery.15 Additionally, innovative advances in the robotic platform have allowed some to perform cases using a single port, which can minimize cosmetic defects even further.16 Although no conclusions on the true clinical benefit of RS compared to open surgery has been reached, current evidence supports its role as a prominent alternative. RS has consistently demonstrated a superior ability to limit blood loss and the amount of analgesia required for patients.17,18 Importantly, for radical cystectomy, partial nephrectomy, and radical nephrectomy, equivalent oncologic outcomes have been seen in patients undergoing robotic versus open surgery.9,19,20 On the other hand, robot-assisted radical prostatectomy may indeed provide advantageous oncologic outcomes. A recent analysis of the National Cancer Database found that RS reduced the rate of surgical margins, need for postoperative radiation therapy, and 30-day mortality compared to open surgery.21 Additionally, robotic prostatectomy has been associated with superior continence rates and sexual function following surgery.22,23 Although the costs of robotic prostatectomy are most often higher than open prostatectomy,4,24 the potential for superior outcomes could support its role as the standard of care for men with prostate cancer.25 This article highlights a potential barrier to further dissemination of RS into clinical practice. At our institution, the da Vinci robot is shared among the urology, gynecology, cardiac, ENT, general, bariatric, colorectal, and surgical oncology faculty as well as private practice surgeons. As such, most surgeons who perform robotic surgical procedures are assigned block times. Here, we demonstrate a hypothetical situation at a single institution where if all urologic procedures that could be performed robotically were done so, a bottleneck effect would have been created by the limited availability of the robot. Twenty additional days would be needed to complete the caseload from the study year, which could take several months depending on the block time available. For example, even for surgeon #1 who had the most block time (8 days per month), it would take 2.5 months more for the caseload to be completed. This could potentially have significant implications for patients. In the oncologic setting, performing curative surgery with minimal delay is necessary. Indeed, extended wait times may have a detrimental effect on not just clinical outcomes, but also on a patient’s anxiety and overall quality of life.26 We believe this highlights an important obstacle to further RS usage. As nearly every urology program now heavily focuses on RS training, urologic surgeons are more comfortable than ever in performing robotic procedures. Similar to how robotic-assisted radical prostatectomy has mostly overtaken open radical prostatectomy as the treatment of choice for prostate cancer, it is not difficult to imagine a scenario in which the vast majority of urologic procedures are performed robotically. Especially in large, tertiary care academic institutions, it is expected that more complex cases will be performed robotically. Surgical innovation and early adaptation of novel and complex robotic approaches can increase the case-load being performed on these robotic systems. Recent reports of robotic cardiothoracic,27 neurosurgical28 and otolaryngological29 procedures suggest that the da Vinci robot may also soon be routinely utilized in these fields as well. This will put even more strain on the ability of surgeons to schedule robotic procedures in a reasonable time period. Increasing the number of systems available would help eliminate this strain, though the costs of doing so are seemingly prohibitive for most organizations. Thus, creative ways to increase the availability of robotic consoles to surgeons must be generated. Additionally, surgeons must continue to practice and refine open and laparoscopic surgical techniques, even in the face of continued robotic innovation and especially for procedures that do not necessarily demonstrate benefit with a RS approach. Future reimbursement models, such as pay-for-performance, and other changes to the health care economy may further factor into which cases can and should be performed robotically versus open or laparoscopically. This article describes a model showing a significant increase in the amount of time it would take to complete a year’s worth of surgical cases if all cases were done robotically. This is of critical importance given a clear conflict on the horizon as the demand for RS from patients and physician training on the robotic platform rises and health care costs continue to increase unsustainably. Further, oncologic implications of performing surgery only when a robotic system is available can potentially make the difference between oncologic cure and metastatic or unresectable disease. This study, however, is not without flaws. First, it is a single institution experience, to which surgery scheduling procedures and practices may not be generalizable to others. Additionally, our model is not very sophisticated as RS feasibility is based on a myriad of factors including surgeon availability, patient availability, and robotic time availability. Further, even when all three align, factors such as patient fitness for RS (both from preoperative clearance standpoint and anatomic feasibility standpoint) will arise and preclude 100% efficiency. Our generalizations of two cases per day save for robotic radical cystectomies, and our inability to look at each individual case based on its complexity, may introduce error into this model. Certainly, a more nuanced system would include numerous other factors (non-urologic surgeons, non-urologic block time, alignment of days of week for scheduling, specific time for each procedure performed, uncommon procedures performed, etc). However, such a model would be very difficult to construct and would be accurate for only the institution studied and hence applicability to other instructions would be limited. This article does however highlight a real logistic consideration that is widely applicable to any institution that is performing RS at or near capacity. Further analyses should be conducted by other high-volume centers in order to fully understand the impact of increased RS utilization. While a high-quality clinical trial evaluating this topic might be difficult to execute, creating a national registry to prospectively collect information on how RS affects the length of time patients must wait to undergo an operation would be extremely valuable.

Conclusion

In summary, we described a hypothetical situation in which all prostatectomies, radical and partial nephrectomies, and cystectomies for one year were done robotically at a single institution. Based on the time available for urologists at the institution to perform robotic surgery, we projected that an extra 32 days would be needed, significantly increasing the waiting time for patients undergoing such operations. As advancements in the field continue, and more surgeons from other specialties begin to integrate RS into clinical practice, the scheduling burden can be expected to increase further. Additional research will be needed to come up with viable solutions to this problem, including evaluating the true clinical utility of robotic surgery.
  29 in total

Review 1.  Evidence from robot-assisted laparoscopic radical prostatectomy: a systematic review.

Authors:  Vincenzo Ficarra; Stefano Cavalleri; Giacomo Novara; Maurizio Aragona; Walter Artibani
Journal:  Eur Urol       Date:  2006-06-30       Impact factor: 20.096

2.  Current status of robotic surgery.

Authors:  Subhasis Giri; Diptendra K Sarkar
Journal:  Indian J Surg       Date:  2012-07-05       Impact factor: 0.656

3.  Perioperative outcomes and oncologic efficacy from a pilot prospective randomized clinical trial of open versus robotic assisted radical cystectomy.

Authors:  Dipen J Parekh; Jamie Messer; John Fitzgerald; Barbara Ercole; Robert Svatek
Journal:  J Urol       Date:  2012-09-24       Impact factor: 7.450

4.  Retroperitoneal lymph node dissection (RPLND) - open surgery's next challenger is ready to enter the ring.

Authors:  Tim Dudderidge
Journal:  BJU Int       Date:  2015-01       Impact factor: 5.588

5.  Comparison of 1800 Robotic and Open Partial Nephrectomies for Renal Tumors.

Authors:  Benoit Peyronnet; Thomas Seisen; Emmanuel Oger; Christophe Vaessen; Yohann Grassano; Thibaut Benoit; Julie Carrouget; Benjamin Pradère; Zineddine Khene; Anthony Giwerc; Romain Mathieu; Jean-Baptiste Beauval; François-Xavier Nouhaud; Pierre Bigot; Nicolas Doumerc; Jean-Christophe Bernhard; Arnaud Mejean; Jean-Jacques Patard; Sharokh Shariat; Morgan Roupret; Karim Bensalah
Journal:  Ann Surg Oncol       Date:  2016-07-13       Impact factor: 5.344

6.  Robotic versus Open Prostatectomy: End of the Controversy.

Authors:  Michael O Koch
Journal:  J Urol       Date:  2016-04-13       Impact factor: 7.450

7.  Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study.

Authors:  John W Yaxley; Geoffrey D Coughlin; Suzanne K Chambers; Stefano Occhipinti; Hema Samaratunga; Leah Zajdlewicz; Nigel Dunglison; Rob Carter; Scott Williams; Diane J Payton; Joanna Perry-Keene; Martin F Lavin; Robert A Gardiner
Journal:  Lancet       Date:  2016-07-26       Impact factor: 79.321

8.  Time trends and local variation in primary treatment of localized prostate cancer.

Authors:  Matthew R Cooperberg; Jeanette M Broering; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

9.  The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples.

Authors:  Brock O'Neil; Tatsuki Koyama; JoAnn Alvarez; Ralph M Conwill; Peter C Albertsen; Matthew R Cooperberg; Michael Goodman; Sheldon Greenfield; Ann S Hamilton; Karen E Hoffman; Richard M Hoffman; Sherrie H Kaplan; Janet L Stanford; Antoinette M Stroup; Lisa E Paddock; Xiao-Cheng Wu; Robert A Stephenson; Matthew J Resnick; Daniel A Barocas; David F Penson
Journal:  J Urol       Date:  2015-09-03       Impact factor: 7.450

10.  Robotic Level III Inferior Vena Cava Tumor Thrombectomy: Initial Series.

Authors:  Inderbir S Gill; Charles Metcalfe; Andre Abreu; Vinay Duddalwar; Sameer Chopra; Mark Cunningham; Duraiyah Thangathurai; Osamu Ukimura; Raj Satkunasivam; Andrew Hung; Rocco Papalia; Monish Aron; Mihir Desai; Michele Gallucci
Journal:  J Urol       Date:  2015-04-06       Impact factor: 7.600

View more
  3 in total

1.  Safety of Prolonged Wait Time for Nephrectomy for Clinically Localized Renal Cell Carcinoma.

Authors:  Nienie Qi; Fangzheng Zhao; Xiaoxiao Liu; Wei Wei; Junqi Wang
Journal:  Front Oncol       Date:  2021-03-30       Impact factor: 6.244

2.  The Impact of New Surgical Techniques on Geographical Unwarranted Variation: The Case of Benign Hysterectomy.

Authors:  Daniel Adrian Lungu; Elisa Foresi; Paolo Belardi; Sabina Nuti; Andrea Giannini; Tommaso Simoncini
Journal:  Int J Environ Res Public Health       Date:  2021-06-22       Impact factor: 3.390

3.  Nephrectomy Delay of More than 10 Weeks from Diagnosis Is Associated with Decreased Overall Survival in pT3 RCC.

Authors:  Jiping Zeng; Ken Batai; Benjamin R Lee
Journal:  J Kidney Cancer VHL       Date:  2021-06-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.